{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:10:59Z","timestamp":1790835059215,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T00:00:00Z","timestamp":1519603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T00:00:00Z","timestamp":1519603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myocardial ischemia\u2013reperfusion injury (IRI) leads to the stabilization of the transcription factors hypoxia-inducible factor 1-alpha (HIF1-alpha) and hypoxia-inducible factor 2-alpha (HIF2-alpha). While previous studies implicate HIF1-alpha in cardioprotection, the role of HIF2-alpha remains elusive. Here we show that HIF2-alpha induces the epithelial growth factor amphiregulin (AREG) to elicit cardioprotection in myocardial IRI. Comparing mice with inducible deletion of <jats:italic>Hif1a<\/jats:italic> or <jats:italic>Hif2a<\/jats:italic> in cardiac myocytes, we show that loss of Hif2-alpha increases infarct sizes. Microarray studies in genetic models or cultured human cardiac myocytes implicate HIF2-alpha in the myocardial induction of AREG. Likewise, AREG increases in myocardial tissues from patients with ischemic heart disease. Areg deficiency increases myocardial IRI, as does pharmacologic inhibition of Areg signaling. In contrast, treatment with recombinant Areg provides cardioprotection and reconstitutes mice with <jats:italic>Hif2a<\/jats:italic> deletion. These studies indicate that HIF2-alpha induces myocardial AREG expression in cardiac myocytes, which increases myocardial ischemia tolerance.<\/jats:p>","DOI":"10.1038\/s41467-018-03105-2","type":"journal-article","created":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T16:23:34Z","timestamp":1519143814000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":120,"title":["Hypoxia-inducible factor 2-alpha-dependent induction of amphiregulin dampens myocardial ischemia-reperfusion injury"],"prefix":"10.1038","volume":"9","author":[{"given":"Michael","family":"Koeppen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Wook","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley S.","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Kreth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana V.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Buttrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Eckle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger K.","family":"Eltzschig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,26]]},"reference":[{"key":"3105_CR1","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/nm.2507","volume":"17","author":"HK Eltzschig","year":"2011","unstructured":"Eltzschig, H. K. & Eckle, T. Ischemia and reperfusion\u2014from mechanism to translation. Nat. Med. 17, 1391\u20131401 (2011).","journal-title":"Nat. Med."},{"key":"3105_CR2","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nrd4422","volume":"13","author":"HK Eltzschig","year":"2014","unstructured":"Eltzschig, H. K., Bratton, D. L. & Colgan, S. P. Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases. Nat. Rev. Drug Discov. 13, 852\u2013869 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3105_CR3","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1056\/NEJMra071667","volume":"357","author":"DM Yellon","year":"2007","unstructured":"Yellon, D. M. & Hausenloy, D. J. Myocardial reperfusion injury. N. Engl. J. Med. 357, 1121\u20131135 (2007).","journal-title":"N. Engl. J. Med."},{"key":"3105_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.molmed.2013.02.005","volume":"19","author":"HK Eltzschig","year":"2013","unstructured":"Eltzschig, H. K., Bonney, S. K. & Eckle, T. Attenuating myocardial ischemia by targeting A2B adenosine receptors. Trends Mol. Med. 19, 345\u2013354 (2013).","journal-title":"Trends Mol. Med."},{"key":"3105_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0140-6736(09)62001-8","volume":"375","author":"HE Botker","year":"2010","unstructured":"Botker, H. E. et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 375, 727\u2013734 (2010).","journal-title":"Lancet"},{"key":"3105_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1056\/NEJMoa071142","volume":"359","author":"C Piot","year":"2008","unstructured":"Piot, C. et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N. Engl. J. Med. 359, 473\u2013481 (2008).","journal-title":"N. Engl. J. Med."},{"key":"3105_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1146\/annurev-physiol-020911-153230","volume":"74","author":"SP Colgan","year":"2012","unstructured":"Colgan, S. P. & Eltzschig, H. K. Adenosine and hypoxia-inducible factor signaling in intestinal injury and recovery. Annu. Rev. Physiol. 74, 153\u2013175 (2012).","journal-title":"Annu. Rev. Physiol."},{"key":"3105_CR8","first-page":"272","volume":"25","author":"CT Taylor","year":"2010","unstructured":"Taylor, C. T. & McElwain, J. C. Ancient atmospheres and the evolution of oxygen sensing via the hypoxia-inducible factor in metazoans. Physiology (Bethesda) 25, 272\u2013279 (2010).","journal-title":"Physiology (Bethesda)"},{"key":"3105_CR9","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nri1685","volume":"5","author":"M Sitkovsky","year":"2005","unstructured":"Sitkovsky, M. & Lukashev, D. Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors. Nat. Rev. Immunol. 5, 712\u2013721 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"3105_CR10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1146\/annurev.immunol.22.012703.104731","volume":"22","author":"MV Sitkovsky","year":"2004","unstructured":"Sitkovsky, M. V. et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu. Rev. Immunol. 22, 657\u2013682 (2004).","journal-title":"Annu. Rev. Immunol."},{"key":"3105_CR11","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1161\/CIRCULATIONAHA.107.758516","volume":"118","author":"T Eckle","year":"2008","unstructured":"Eckle, T., Kohler, D., Lehmann, R., El Kasmi, K. C. & Eltzschig, H. K. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation 118, 166\u2013175 (2008).","journal-title":"Circulation"},{"key":"3105_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/cvr\/cvm035","volume":"77","author":"Z Cai","year":"2008","unstructured":"Cai, Z. et al. Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1 alpha. Cardiovasc. Res. 77, 463\u2013470 (2008).","journal-title":"Cardiovasc. Res."},{"key":"3105_CR13","doi-asserted-by":"publisher","first-page":"17462","DOI":"10.1073\/pnas.1317158110","volume":"110","author":"Z Cai","year":"2013","unstructured":"Cai, Z., Luo, W., Zhan, H. & Semenza, G. L. Hypoxia-inducible factor 1 is required for remote ischemic preconditioning of the heart. Proc. Natl. Acad. Sci. USA 110, 17462\u201317467 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3105_CR14","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/nm.2728","volume":"18","author":"T Eckle","year":"2012","unstructured":"Eckle, T. et al. Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia. Nat. Med. 18, 774\u2013782 (2012).","journal-title":"Nat. Med."},{"key":"3105_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2008.10.001","volume":"9","author":"J Aragones","year":"2009","unstructured":"Aragones, J., Fraisl, P., Baes, M. & Carmeliet, P. Oxygen sensors at the crossroad of metabolism. Cell. Metab. 9, 11\u201322 (2009).","journal-title":"Cell. Metab."},{"key":"3105_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrd2761","volume":"8","author":"P Fraisl","year":"2009","unstructured":"Fraisl, P., Aragones, J. & Carmeliet, P. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat. Rev. Drug. Discov. 8, 139\u2013152 (2009).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"3105_CR17","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1172\/JCI69073","volume":"124","author":"PP Kapitsinou","year":"2014","unstructured":"Kapitsinou, P. P. et al. Endothelial HIF-2 mediates protection and recovery from ischemic kidney injury. J. Clin. Invest. 124, 2396\u20132409 (2014).","journal-title":"J. Clin. Invest."},{"key":"3105_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1089\/ars.2009.3014","volume":"13","author":"I Diebold","year":"2010","unstructured":"Diebold, I. et al. The hypoxia-inducible factor-2alpha is stabilized by oxidative stress involving NOX4. Antioxid. Redox Signal. 13, 425\u2013436 (2010).","journal-title":"Antioxid. Redox Signal."},{"key":"3105_CR19","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1091\/mbc.E09-12-1003","volume":"21","author":"I Diebold","year":"2010","unstructured":"Diebold, I., Petry, A., Hess, J. & Gorlach, A. The NADPH oxidase subunit NOX4 is a new target gene of the hypoxia-inducible factor-1. Mol. Biol. Cell. 21, 2087\u20132096 (2010).","journal-title":"Mol. Biol. Cell."},{"key":"3105_CR20","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1056\/NEJMra0910283","volume":"364","author":"HK Eltzschig","year":"2011","unstructured":"Eltzschig, H. K. & Carmeliet, P. Hypoxia and inflammation. N. Engl. J. Med. 364, 656\u2013665 (2011).","journal-title":"N. Engl. J. Med."},{"key":"3105_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1161\/hh1301.092687","volume":"89","author":"DS Sohal","year":"2001","unstructured":"Sohal, D. S. et al. Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ. Res. 89, 20\u201325 (2001).","journal-title":"Circ. Res."},{"key":"3105_CR22","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/onc.2010.433","volume":"30","author":"MR Bordoli","year":"2011","unstructured":"Bordoli, M. R. et al. Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis. Oncogene 30, 548\u2013560 (2011).","journal-title":"Oncogene"},{"key":"3105_CR23","doi-asserted-by":"publisher","first-page":"C592","DOI":"10.1152\/ajpcell.00278.2005","volume":"290","author":"SM O\u2019Reilly","year":"2006","unstructured":"O\u2019Reilly, S. M. et al. Hypoxia induces epithelial amphiregulin gene expression in a CREB-dependent manner. Am. J. Physiol. Cell Physiol. 290, C592\u2013C600 (2006).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"3105_CR24","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1242\/dev.126.12.2739","volume":"126","author":"NC Luetteke","year":"1999","unstructured":"Luetteke, N. C. et al. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 126, 2739\u20132750 (1999).","journal-title":"Development"},{"key":"3105_CR25","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/73528","volume":"24","author":"B Chen","year":"2000","unstructured":"Chen, B. et al. Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nat. Genet. 24, 296\u2013299 (2000).","journal-title":"Nat. Genet."},{"key":"3105_CR26","first-page":"H2205","volume":"277","author":"KS Russell","year":"1999","unstructured":"Russell, K. S., Stern, D. F., Polverini, P. J. & Bender, J. R. Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am. J. Physiol. 277, H2205\u2013H2211 (1999).","journal-title":"Am. J. Physiol."},{"key":"3105_CR27","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1016\/S0021-9258(18)53862-X","volume":"268","author":"GR Johnson","year":"1993","unstructured":"Johnson, G. R., Kannan, B., Shoyab, M. & Stromberg, K. Amphiregulin induces tyrosine phosphorylation of the epidermal growth-factor receptor andp185(ERBB2)\u2014evidence that amphiregulin acts exclusively through the epidermal growth-factor receptor at the surface of human epithelial-cells. J. Biol. Chem. 268, 2924\u20132931 (1993).","journal-title":"J. Biol. Chem."},{"key":"3105_CR28","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.bcp.2006.01.020","volume":"71","author":"AG Ellis","year":"2006","unstructured":"Ellis, A. G. et al. Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochem. Pharmacol. 71, 1422\u20131434 (2006).","journal-title":"Biochem. Pharmacol."},{"key":"3105_CR29","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/S0959-8049(01)00233-7","volume":"37","author":"J Baselga","year":"2001","unstructured":"Baselga, J. The EGFR as a target for anticancer therapy--focus on cetuximab. Eur. J. Cancer 37, S16\u2013S22 (2001). Suppl 4.","journal-title":"Eur. J. Cancer"},{"key":"3105_CR30","doi-asserted-by":"crossref","unstructured":"Goldberg, R. M. Cetuximab. Nat. Rev. Drug Discov. (Suppl.) S10\u2013S11 (2005).","DOI":"10.1038\/nrd1728"},{"key":"3105_CR31","doi-asserted-by":"publisher","first-page":"5558","DOI":"10.1158\/1078-0432.CCR-05-0368","volume":"11","author":"FR Luo","year":"2005","unstructured":"Luo, F. R. et al. Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model. Clin. Cancer Res. 11, 5558\u20135565 (2005).","journal-title":"Clin. Cancer Res."},{"key":"3105_CR32","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nm.4078","volume":"22","author":"C Pozzi","year":"2016","unstructured":"Pozzi, C. et al. The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. Nat. Med. 22, 624\u2013631 (2016).","journal-title":"Nat. Med."},{"key":"3105_CR33","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1161\/01.CIR.104.3.330","volume":"104","author":"T Matsui","year":"2001","unstructured":"Matsui, T. et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 104, 330\u2013335 (2001).","journal-title":"Circulation"},{"key":"3105_CR34","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nm721","volume":"8","author":"V Compernolle","year":"2002","unstructured":"Compernolle, V. et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat. Med. 8, 702\u2013710 (2002).","journal-title":"Nat. Med."},{"key":"3105_CR35","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1172\/JCI5912","volume":"103","author":"AY Yu","year":"1999","unstructured":"Yu, A. Y. et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1{alpha}. J. Clin. Invest. 103, 691\u2013696 (1999).","journal-title":"J. Clin. Invest."},{"key":"3105_CR36","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1093\/emboj\/17.11.3005","volume":"17","author":"HE Ryan","year":"1998","unstructured":"Ryan, H. E., Lo, J. & Johnson, R. S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 17, 3005\u20133015 (1998).","journal-title":"EMBO J."},{"key":"3105_CR37","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/cvr\/cvu255","volume":"105","author":"M Du","year":"2015","unstructured":"Du, M. et al. Renalase is a novel target gene of hypoxia-inducible factor-1 in protection against cardiac ischaemia-reperfusion injury. Cardiovasc. Res. 105, 182\u2013191 (2015).","journal-title":"Cardiovasc. Res."},{"key":"3105_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/cvr\/cvu172","volume":"104","author":"SG Ong","year":"2014","unstructured":"Ong, S. G. et al. HIF-1 reduces ischaemia-reperfusion injury in the heart by targeting the mitochondrial permeability transition pore. Cardiovasc. Res. 104, 24\u201336 (2014).","journal-title":"Cardiovasc. Res."},{"key":"3105_CR39","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1089\/ars.2010.3769","volume":"15","author":"RS Adluri","year":"2011","unstructured":"Adluri, R. S. et al. Disruption of hypoxia-inducible transcription factor-prolyl hydroxylase domain-1 (PHD-1-\/-) attenuates ex vivo myocardial ischemia\/reperfusion injury through hypoxia-inducible factor-1alpha transcription factor and its target genes in mice. Antioxid. Redox Signal. 15, 1789\u20131797 (2011).","journal-title":"Antioxid. Redox Signal."},{"key":"3105_CR40","doi-asserted-by":"publisher","first-page":"13646","DOI":"10.1074\/jbc.M109.084855","volume":"285","author":"J Hyvarinen","year":"2010","unstructured":"Hyvarinen, J. et al. Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury. J. Biol. Chem. 285, 13646\u201313657 (2010).","journal-title":"J. Biol. Chem."},{"key":"3105_CR41","doi-asserted-by":"publisher","first-page":"11185","DOI":"10.1074\/jbc.M110.186809","volume":"286","author":"M Holscher","year":"2011","unstructured":"Holscher, M. et al. Cardiomyocyte-specific prolyl-4-hydroxylase domain 2 knock out protects from acute myocardial ischemic injury. J. Biol. Chem. 286, 11185\u201311194 (2011).","journal-title":"J. Biol. Chem."},{"key":"3105_CR42","doi-asserted-by":"publisher","first-page":"10504","DOI":"10.1073\/pnas.1208314109","volume":"109","author":"K Sarkar","year":"2012","unstructured":"Sarkar, K. et al. Hypoxia-inducible factor 1 transcriptional activity in endothelial cells is required for acute phase cardioprotection induced by ischemic preconditioning. Proc. Natl. Acad. Sci. USA 109, 10504\u201310509 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3105_CR43","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1038\/onc.2011.417","volume":"31","author":"DP Stiehl","year":"2012","unstructured":"Stiehl, D. P. et al. Non-canonical HIF-2alpha function drives autonomous breast cancer cell growth via an AREG-EGFR\/ErbB4 autocrine loop. Oncogene 31, 2283\u20132297 (2012).","journal-title":"Oncogene"},{"key":"3105_CR44","doi-asserted-by":"publisher","unstructured":"Carvalho, S. et al. An antibody to amphiregulin, an abundant growth factor in patients\u2019 fluids, inhibits ovarian tumors. Oncogene. https:\/\/doi.org\/10.1038\/onc.2015.93 (2015).","DOI":"10.1038\/onc.2015.93"},{"key":"3105_CR45","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1016\/S0014-4827(08)00404-7","volume":"314","author":"A Sorkin","year":"2008","unstructured":"Sorkin, A. & Goh, L. K. Endocytosis and intracellular trafficking of ErbBs. Exp. Cell Res. 314, 3093\u20133106 (2008).","journal-title":"Exp. Cell Res."},{"key":"3105_CR46","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/j.cellsig.2006.05.015","volume":"18","author":"ES Henson","year":"2006","unstructured":"Henson, E. S. & Gibson, S. B. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell Signal. 18, 2089\u20132097 (2006).","journal-title":"Cell Signal."},{"key":"3105_CR47","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/ncb1101-973","volume":"3","author":"BP Zhou","year":"2001","unstructured":"Zhou, B. P. et al. HER-2\/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3, 973\u2013982 (2001).","journal-title":"Nat. Cell Biol."},{"key":"3105_CR48","doi-asserted-by":"publisher","unstructured":"Rossello, X., Riquelme, J. A., Davidson, S. M. & Yellon, D. M. Role of PI3K in myocardial ischaemic preconditioning: mapping pro-survival cascades at the trigger phase and at reperfusion. J. Cell Mol. Med. https:\/\/doi.org\/10.1111\/jcmm.13394 (2017).","DOI":"10.1111\/jcmm.13394"},{"key":"3105_CR49","doi-asserted-by":"publisher","first-page":"25903","DOI":"10.1074\/jbc.M603414200","volume":"281","author":"XH Peng","year":"2006","unstructured":"Peng, X. H. et al. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J. Biol. Chem. 281, 25903\u201325914 (2006).","journal-title":"J. Biol. Chem."},{"key":"3105_CR50","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1136\/jcp.55.11.801","volume":"55","author":"PA Krijnen","year":"2002","unstructured":"Krijnen, P. A. et al. Apoptosis in myocardial ischaemia and infarction. J. Clin. Pathol. 55, 801\u2013811 (2002).","journal-title":"J. Clin. Pathol."},{"key":"3105_CR51","doi-asserted-by":"publisher","first-page":"H1923","DOI":"10.1152\/ajpheart.00935.2003","volume":"286","author":"JD McCully","year":"2004","unstructured":"McCully, J. D., Wakiyama, H., Hsieh, Y. J., Jones, M. & Levitsky, S. Differential contribution of necrosis and apoptosis in myocardial ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 286, H1923\u2013H1935 (2004).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"3105_CR52","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.immuni.2012.09.023","volume":"38","author":"DM Zaiss","year":"2013","unstructured":"Zaiss, D. M. et al. Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. Immunity 38, 275\u2013284 (2013).","journal-title":"Immunity"},{"key":"3105_CR53","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.immuni.2015.01.020","volume":"42","author":"DM Zaiss","year":"2015","unstructured":"Zaiss, D. M., Gause, W. C., Osborne, L. C. & Artis, D. Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair. Immunity 42, 216\u2013226 (2015).","journal-title":"Immunity"},{"key":"3105_CR54","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.cell.2013.10.054","volume":"155","author":"D Burzyn","year":"2013","unstructured":"Burzyn, D. et al. A special population of regulatory T cells potentiates muscle repair. Cell 155, 1282\u20131295 (2013).","journal-title":"Cell"},{"key":"3105_CR55","doi-asserted-by":"publisher","first-page":"20813","DOI":"10.1074\/jbc.M114.575464","volume":"289","author":"H Makinoshima","year":"2014","unstructured":"Makinoshima, H. et al. Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma. J. Biol. Chem. 289, 20813\u201320823 (2014).","journal-title":"J. Biol. Chem."},{"key":"3105_CR56","doi-asserted-by":"publisher","first-page":"II280","DOI":"10.1161\/01.CIR.0000138974.18839.02","volume":"110","author":"P Voisine","year":"2004","unstructured":"Voisine, P. et al. Differences in gene expression profiles of diabetic and nondiabetic patients undergoing cardiopulmonary bypass and cardioplegic arrest. Circulation 110, II280\u2013II286 (2004).","journal-title":"Circulation"},{"key":"3105_CR57","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/ALN.0b013e318255793c","volume":"116","author":"M Koeppen","year":"2012","unstructured":"Koeppen, M. et al. Adora2b signaling on bone marrow derived cells dampens myocardial ischemia-reperfusion injury. Anesthesiology 116, 1245\u20131257 (2012).","journal-title":"Anesthesiology"},{"key":"3105_CR58","first-page":"2526","volume":"19","author":"T Eckle","year":"2011","unstructured":"Eckle, T., Koeppen, M. & Eltzschig, H. Use of a hanging weight system for coronary artery occlusion in mice. J. Vis. Exp. 19, 2526 (2011).","journal-title":"J. Vis. Exp."},{"key":"3105_CR59","doi-asserted-by":"publisher","first-page":"H2533","DOI":"10.1152\/ajpheart.00472.2006","volume":"291","author":"T Eckle","year":"2006","unstructured":"Eckle, T. et al. Systematic evaluation of a novel model for cardiac ischemic preconditioning in mice. Am. J. Physiol. Heart Circ. Physiol. 291, H2533\u2013H2540 (2006).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"3105_CR60","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45 (2001).","journal-title":"Nucleic Acids Res."},{"key":"3105_CR61","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1002\/elps.200800720","volume":"30","author":"M Gassmann","year":"2009","unstructured":"Gassmann, M., Grenacher, B., Rohde, B. & Vogel, J. Quantifying western blots: pitfalls of densitometry. Electrophoresis 30, 1845\u20131855 (2009).","journal-title":"Electrophoresis"},{"key":"3105_CR62","doi-asserted-by":"publisher","first-page":"15871","DOI":"10.1073\/pnas.2036503100","volume":"100","author":"TG Johns","year":"2003","unstructured":"Johns, T. G. et al. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc. Natl. Acad. Sci. USA 100, 15871\u201315876 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-03105-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-03105-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-03105-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:11:44Z","timestamp":1671541904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-03105-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,26]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["3105"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-03105-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,26]]},"assertion":[{"value":"15 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing\u00a0financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"816"}}